Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 09, 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of...
Vaccitech to Present at the William Blair Biotech Focus Conference 2022
July 07, 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech 的 VTP-300 作為單藥治療和與單次低劑量抗 PD-1 聯合使用均可誘導慢性乙型肝炎患者的表面抗原持續減少
June 23, 2022 07:37 ET
|
Vaccitech (UK) Limited
VTP-300 作為單藥治療和與單次給藥的低劑量納武利單抗聯合使用時，沒有出現與治療相關的嚴重不良事件和罕見的短暫性轉氨酶升高。 在一些接受 VTP-300 作為單藥治療或與單次低劑量納武利單抗作加強劑量聯合治療的患者中，可觀察到乙型肝炎表面抗原 (HBsAg) 顯著和持久降低。在乙型肝炎表面抗原基線較低的患者中，下降最為顯著。 所有接受 VTP-300...
Vaccitech의 VTP-300, 만성 B형 간염 환자에게 단일요법으로, 또는 저용량의 PD-1 항체 1회와 함께 투여될 시 표면항원의 지속적인 감소 유발
June 23, 2022 07:37 ET
|
Vaccitech (UK) Limited
VTP-300을 단일요법으로, 또는 저용량의 니볼루맙을 1회 함께 투여했을 때, 치료를 요하는 위중한 부작용은 나타나지 않았으며, 낮은 확률로 발현된 아미노전이염은 일시적이었음. VTP-300을 단일요법으로, 또는 2차 접종 시 저용량의 니볼루맙을 1회 함께 투여했을 때, 일부 환자에게서 유의미하고 지속적인 B형 간염 표면항원(HBsAg) 감소...
无论是作为单一疗法还是与单一低剂量抗PD-1联合使用，Vaccitech的VTP-300都可持续降低慢性乙型肝炎患者的表面抗原
June 23, 2022 07:37 ET
|
Vaccitech (UK) Limited
VTP-300无论是作为一种单药，或是与一种低剂量纳武单药给药联合使用，均未出现与治疗相关的严重不良事件和罕见的短暂性转氨酶升高现象。 在接受VTP-300作为单药治疗或在增强剂量下与单一低剂量纳武联合使用的一些患者中，可以看到乙型肝炎表面抗原（HBsAg）呈现有意义且持久减少。在HBsAg基准较低的患者中，下降最为突出。 ...
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
June 22, 2022 06:00 ET
|
Vaccitech plc
VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient...
Vaccitech to Present at the Jefferies Healthcare Conference
June 06, 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
June 06, 2022 07:32 ET
|
Vaccitech plc
WARMINSTER, Pa. and OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus 和 Vaccitech 藥物在 2a 期臨床試驗中為首位患者進行慢性乙型肝炎病毒給藥聯合療法
June 04, 2022 09:43 ET
|
Vaccitech (UK) Limited
美國賓州的沃明斯特和英國牛津, June 04, 2022 (GLOBE NEWSWIRE) -- 专注臨床階段的生物製藥公司 Arbutus Biopharma Corporation (Nasdaq: ABUS）利用自身廣泛的病毒學專業知識，開發針對特定病毒性疾病的新療法，聯合從事發現和開發新型免疫療法和疫苗的臨床階段生物製藥公司 Vaccitech plc (Nasdaq:...
Arbutus和Vaccitech在2a期临床试验中联合慢性乙型肝炎病毒治疗方法向首例患者进行给药
June 04, 2022 09:43 ET
|
Vaccitech (UK) Limited
宾夕法尼亚州沃明斯特和英国牛津, June 04, 2022 (GLOBE NEWSWIRE) -- 致力于利用广泛的病毒学专业知识开发靶向特定病毒性疾病新型疗法的临床阶段生物制药公司Arbutus Biopharma Corporation（纳斯达克股票代码：ABUS）以及从事新型免疫疗法和疫苗发现及开发的临床阶段生物制药公司Vaccitech...